The phthalate ester di(2-ethylhexyl) phthalate is both a peroxisome proliferator and a hepatic carcinogen. Peroxisome proliferators as a class are hepatocarcinogenic in rodent species. However, none of the peroxisome proliferators tested to date including the phthalate esters and related alcohol and acid analogs have demonstrated mutagenic or DNA;damaging activity in the in vitro Salmonella typhimurium/microsomal or the lymphocyte 3H-thymidine assays. A working hypothesis is proposed that peroxisome proliferation itself initiates neoplastic transformation of hepatic parenchymal cells by increasing intracellular rates of DNA-damaging reactive oxygen production. Evidence which supports such a hypothesis includes increased fatty acid ,-oxidation, elevated H202 levels, accumulation of peroxidized lipofuscin, disproportionately small increase in catalase, and elevated peroxisomal uricase activity which accompany peroxisome proliferation in hepatocytes. Direct testing of this hypothesis will provide insight into mechanisms of phthalate ester carcinogenicity and cytotoxicity.
A xenobiotic which induces the proliferation of peroxisomes in liver cells is designated a peroxisome proliferator. Peroxisomes (microbodies) are single membrane-limited cytoplasmic organelles which functionally have been implicated in gluconeogenesis, lipid metabolism, and the detoxification of H202. The hypolipidemic agent clofibrate was the first xenobiotic to be identified as a peroxisome proliferator (1, 2) . Subsequently a large number of other xenobiotics have been discovered to be peroxisome proliferators, including structural analogs of clofibrate (nafenopin, methyl cofenapate, SaH-42, 348, and gemfibrozil), hypolipidemic drugs structurally unrelated to clofibrate (tibric acid, Wy-14,643, BR-931), and a group of miscellaneous compounds which were not developed for pharmacological utilization as hypolipidemic drugs but were incidentally discovered to express activity as peroxisome proliferators (3, 4) . The industrial plasticizer di(2-ethylhexyl) phthalate (DEHP) and related plasticizers, including di(2-ethylhexyl) adipate, are important members of the miscellaneous peroxisome proliferators group (Fig. 1 ). All peroxisome proliferators studied to date, including DEHP, have been observed to induce hepatomegaly and hypotriglyceridemia when fed to rodents (5, 6) .
Sustained peroxisome proliferation in rodent liver has been associated with an increased appearance ofhepatocellular carcinoma. Peroxisome proliferators which have demonstrated hepatocarcinogenicity in rodents include nafenopin (7), Wy-14,643 (8) , clofibrate (9) , BR-931 and tibric acid (10) . The development of liver tumors in animals fed these five structurally diverse hypolipidemic drugs led to the conclusion that peroxisome proliferators as a class are carcinogenic (10) . Since the formulation of this hypothesis, the industrial plasticizer DEHP has been observed to induce hepatocellular neoplasms in both F-344 rats and B6C3F1 mice (11) . The reported carcinogenicity of DEHP in rodents is particularly disturbing, since DEHP is a common environmental contaminant (12, 13) and it is probable that human exposure to DEHP has been extensive. Our laboratories are currently investigating cellular/molecular mechanisms involved in peroxisome proliferator carcinogenesis, including DEHP and related plasticizers. In this report, possible mechanisms of peroxisome proliferator carcinogenesis based on current knowledge of the properties of these xenobiotics will be reviewed.
Current models of carcinogenesis indicate both an initiation and promotion phase in the formation WARREN, LALWANI AND REDDY FIGURE 1. Proliferation of peroxisomes induced in F-344 rat liver cell cytoplasm by DEHP. 18,000 x. of neoplasms (14) . Initiation of cells for neoplastic transformation is irreversible and requires interactions of nucleophilic centers in cellular DNA with electrophilic regions of chemical carcinogens or carcinogen metabolites (14) . An estimate of the electrophilic reactivity of carcinogens can be obtained by mutagenicity measurements. We have tested five different hypolipidemic drugs (clofibrate, nafenopin, SaH-42-348, Wy-14,643 and BR-931), both structurally related and structurally unrelated to clofibrate, for in vitro mutagenic activity against each of the different Salmonella typhimurium test strains TA98, TA100, TA1535, TA1537 and TA1538.
The hypolipidemic drugs, whether tested without or with rat liver S-9 microsomal preparation, were uniformly negative as mutagens in the Ames S. typhimurium assay (15) . Our results have been extended by de la Iglesia and his co-workers (16) , who reported that the hypolipidemic drug gemfibrozil or five in vivo metabolites of gemfibrozil isolated from rat urine were without mutagenic activity toward the same S. typhimurium tester strains utilized by us. Gemfibrozil is both a peroxisome proliferator and hepatocarcinogen in rats (5) . Also, methyl clofenapate in very recent work was not mutagenic in the Salmonella/microsome assay with tester strains TA98 and TA100 (17) . We have also utilized the lymphocyte 3H-thymidine assay to test the five hypolipidemic drugs found by us to be negative in the Ames assay plus tibric acid for electrophilic reactivity. The hypolipidemic agents, tested either with or without rat liver S-9 microsomal preparation, resembled nonmutagenic drugs and not mutagenic carcinogens in the lymphocyte 3H-thymidine assay (15) . These data indicate, therefore, that the hypolipidemic agents fail to behave as electrophilic reactants capable ofcovalent interaction with cellular nucleic acid.
In preliminary work, we have tested plasticizers and related compounds for reactivity in both the Salmonella/microsome and the lymphocyte 3H-thymidine assay. A dose-dependent increase in the number ofHis + revertant colonies was not observed over a wide concentration range of the plasticizers DEHP and di(2-ethylhexyl) adipate (DEHA) when tested in the absence or presence of rat liver S-9 microsomal mixture with S. typhimurium strains TA98 and TA100 (Table 1) . The related compounds, 36 PHTHALATE ESTERS AS PEROXISOME PROLIFERATOR CARCINOGENS as. typhimurium TA98 and TA100 were incubated in the absence or presence of S-9 microsomal mixture on histidine-deficient agar with carcinogen or plasticizers for 2 days at 37°C.
bAs a positive control, the indirect carcinogen 2-acetylaminofluorene (10 ,ug/plate) added in the presence of S-9 microsomal mixture was included in each experiment. In the experiment with strain TA98, 690 revertant colonies were counted per plate and with strain TA100, 353 revertant colonies per plate.
ethyl-2-hexanol and ethylhexanoic acid, were also without mutagenic activity in the Ames assay (Table 1) . Both 2-ethylhexyl alcohol and 2-ethylhexanoic acid are potent peroxisome proliferators and it has been suggested that 2-ethylhexyl alcohol is the active part of the DEHP or DEHA molecule responsible for peroxisome proliferation (4). Also, 2-ethylhexyl alcohol is a metabolite of DEHP. In the lymphocyte 3H-thymidine assay, DEHP, DEHA and ethyl-2-hexanol induced a dose-dependent inhibition of 3H-thymidine incorporation into the replicating DNA of proliferating (concanavalin Astimulated) C57BL/6J splenic lymphoid cells ( Table   2 ). The dose-dependent inhibition of 3H-thymidine incorporation into replicating DNA was accompanied by a dose-dependent increase in the ratio of acid-soluble to DNA-incorporated 3H-thymidine in the plasticizer-treated lymphocytes ( (20) , and peroxisome proliferators have been found to increase manyfold the capacity of rat liver for the 1-oxidation of fatty acids (21) . In particular, the administration of DEHP resulted in a substantial increase in peroxisomal palmitoyl-CoA oxidation in liver homogenates (22) . A similar increase in the peroxisomal fatty acyl-CoA-oxidation system has been detected following the administration of other peroxisome proliferators, including clofibrate, nafenopin, Wy-14,643, tibric acid, gemfibrozil and methyl clofenapate (5). Peroxisomal fatty acyl-CoA oxidation appears to be independent of an electron transport chain and results in the production of H202 by direct transfer of electrons to 02. A sevenfold increase in the rate of palmitoyl CoA-dependent H202 generation has been detected in the liver of rats administered nafenopin (23) . Liver eCells were incubated for 2.5 hr without or with plasticizer plus 20% (v/v) S-9 microsomal mixture. (26, 27) . Also, H202 has been found to induce DNA scissions in intact prokaryotic and eukaryotic cells (28, 29) and chromatid breaks, chromatid exchanges and unscheduled DNA synthesis in intact mammalian cells (30, 31) . The important possibility arises, therefore, that sustained peroxisome proliferation initiates cells for neoplastic transformation by increasing intracellular production of DNA-damaging oxygen species. Further changes in peroxisomal enzyme profiles induced by the peroxisome proliferators can be cited which could serve to increase cellular reactive oxygen species. First, the increase in peroxisomal catalase activity is disproportionately small compared to the increase in peroxisome volume (32) and H202-generating fatty acid ,B-oxidation (33) induced by the peroxisome proliferators. It will be recalled that catalase catalyzes the degradation of H202. Second, a substantial level of uricase activity has been detected in the peroxisomes of rodent liver (34) . Although serum and tissue levels of uric acid have yet to be systematically measured in animals treated with peroxisome proliferators, increased levels of hepatic uricase would result in decreased levels of uric acid. Uric acid is a powerful antioxidant and is a scavenger of oxygen radicals (35) . (36) . Tumor promotion is a reversible process which, unlike initiation, appears not to depend upon covalent modification of biological macromolecules (14) . However, mechanisms of tumor promotion are poorly understood, and proposed cellular/molecular mechanisms ofpromotion as of the date of this report (14) would add little to a basic understanding ofphthalate ester carcinogenesis.
As a final note, we should stress that chemically induced peroxisome proliferation is not limited to rats and mice. Hepatic peroxisome proliferation has been induced by hypolipidemic drugs in hamsters, pigeons, chickens, cats, and rhesus monkeys (37, 38) . Also, ultrastructural changes in the liver of human subjects on long-term (6 months to 7 years) clofibrate therapy included an elevated number of microbodies (peroxisomes) (39) . Consequently, the potential importance of peroxisome proliferator carcinogenesis impacts on many species including the human.
